Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

by Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt, Josef S. Smolen
Published 2020-05-01

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

by Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt, Josef S. Smolen
Published 2020-07-01

Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

by Elizabeth D. Bacci, Amy M. DeLozier, Chen-Yen Lin, Carol L. Gaich, Terence Rooney, Richard Hoffman, Kathleen W. Wyrwich
Published 2017-12-01

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

by Elizabeth D. Bacci, Amy M. DeLozier, Chen-Yen Lin, Carol L. Gaich, Xiang Zhang, Terence Rooney, Stephanie de Bono, Richard Hoffman, Kathleen W. Wyrwich
Published 2017-12-01

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

by Michael Schiff, Tsutomu Takeuchi, Roy Fleischmann, Carol L. Gaich, Amy M. DeLozier, Douglas Schlichting, Wen-Ling Kuo, Ji-Eon Won, Tara Carmack, Terence Rooney, Patrick Durez, Saeed Shaikh, Rodolfo Pardo Hidalgo, Ronald van Vollenhoven, Cristiano A. F. Zerbini
Published 2017-09-01